DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for pancreatic serous cystadenocarcinoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePancreatic serous cystadenocarcinoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pancreatic serous cystadenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
What the evidence adds up to
Pancreatic serous cystadenocarcinoma is a disputed diagnosis. The 2010 World Health Organization definition requires metastases or invasion of adjacent organs, but the authors of a 2013 review found that none of the reported cases showed clear histopathological features of malignancy. No patient in that review died from causes specifically related to serous cystadenocarcinoma, even those with metastatic disease. The authors concluded that several cases labelled as serous cystadenocarcinoma are not convincing.
A 1991 case report describes a 66-year-old woman who underwent surgery for a presumed cystadenocarcinoma of the pancreatic body. The tumour measured 4 × 4.5 cm, was clearly demarcated, and contained microcysts with serous fluid. Histopathology showed pancreatic serous cystadenoma with no finding of malignancy. A 2024 case report confirms that the vast majority of serous cystadenomas are benign, and describes extensive degeneration that can mimic a pancreatic pseudocyst.
The evidence base consists of small case reports and a single review that questions whether the malignant entity exists at all. No clinical trial data, no survival statistics, and no response rates are available for any drug treatment. What is missing is a clear, histologically confirmed case series that meets modern diagnostic criteria, prospective registry data, and any trial design that could test a drug in a disease whose malignant potential remains unproven.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the Korean Surgical Society · 2011 · 22 citations · open access
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen
AbstractSerous cystic neoplasms of the pancreas are almost always benign lesions. However, there are some case reports of malignant serous neoplasms of the pancreas. It is very difficult to distinguish malignant and benign tumors. Indeed, only clinicopathologic findings of locoregional invasion and metastasis represent a malignancy. We report a serous cystadenocarcinoma of the pancreas that was initially considered to be colon cancer. Post-operatively, the tumor was confirmed to be a malignant serous cystic tumor of the pancreas. One year later, the patient remains disease-free.
Pancreatic Disorders and Therapy · 2013 · 2 citations
Pancreatic Serous Cystadenocarcinoma: Are You Really So Malignant?
AbstractIn 2010 the World Health Organization described pancreatic serous cystadenocarcinoma (SCAC) as a serous cystadenoma that presents metastases or invasion of adjacent organs. Although a handful of cases have been described in literature, this entity shows some discrepancies. The dilemma can arise starting on the concept of “metastases” and “invasion”: any of reported SCAC shows clear histopathological features of malignancy. Moreover no patient deceased for reasons specifically related to SCAC, even those with metastatic disease. For these reasons, several cases defined as SCACs are not convincing.
The journal of the Japanese Practical Surgeon Society · 1991 · 0 citations · open access
A RESECTED CASE OF PANCREATIC SEROUS CYSTADENOMA
AbstractWe experienced a case of pancreatic serous cystadenoma found in an inpatient treated for indefinite complaints. The patient was a 66-year-old woman with the chief complaint of numbness of her both hands without any digestive symptoms. Abdominal ultrasonography and CT showed a tumor picture, ERP did an exclusive picture of the pancreatic duct, and a slightly hypervascular pattern by angiography. The patient was diagnosed as having a cystadenocarcinoma of the pancreatic body and operation was carried out. The tumor disclosed 4×4.5 cm in size, clearly demarcated picture, cleavage surface with many microcysts containing serosity like substance. Histopathologically, it was pancreatic serous cystadenoma with no finding of malignancy.
Unlucky microcystic serous cystoadenoma. A case report of an unexpected degeneration
AbstractAims Pancreatic serous cystadenoma (SCA) is a benign neoplastic lesion with a distinctive gross and microscopic appearance consisting of numerous thin-walled cysts lined by uniform epithelial cells with clear cytoplasm and small nuclei. The vast majority of serous cystadenomas are benign. Extensive degeneration mimicking a pancreatic pseudocyst has been described in several types of pancreatic neoplasms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
